Trial Profile

A Phase IIa of Infigratinib in Subjects With Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma With FGFR2 Amplification or Other Advanced Solid Tumors With Other FGFR Alterations

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infigratinib (Primary)
Indications Adenocarcinoma; Carcinoma; Cholangiocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
Focus Proof of concept; Therapeutic Use
Acronyms FGFR
Sponsors LianBio

25 Oct 2023 According to a LianBio media release, results from this trial were presented at the 2023 European Society for Medical Oncology (ESMO) Congress.
25 Oct 2023 Results presented in the LianBio Media Release.
24 Oct 2023 Results of cohort 1 assessing efficacy and safety of infigratinib monotherapy in previously systemic second-line treated patients harbouring FGFR2 gene amplification., presented at the 48th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com